Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex

Neurology

Volumn 57, Issue 5, 2001, Pages 805-811

  Lai, M K P ^a,b   Lai, O F ^a   Keene, J ^c   Esiri, M M ^c   Francis, P T ^d   Hope, T ^c   Chen, Christopher P L H ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b University of Sydney   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; RADIOLIGAND;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CHOLINERGIC SYSTEM; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; HUMAN; LIGAND BINDING; MALE; NEUROCHEMISTRY; NEUROPSYCHIATRY; PRIORITY JOURNAL; PSYCHOSIS; TEMPORAL CORTEX;

EID: 0035845705     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.57.5.805     Document Type: Article

References (45)

1. The cholinergic hypothesis of Alzheimer's disease: A review of progress
2. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue
3. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
4. Presynaptic cholinergic dysfunction in patients with dementia
5. Alzheimer's disease: Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities
6. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment
7. Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases
8. 2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation
9. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases
10. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
11. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
12. Physostigmine ameliorates the delusions of Alzheimer's disease
13. Cholinesterase inhibitors: A new class of psychotropic compounds
14. The spectrum of behavioral changes in Alzheimer's disease
15. Behaviour changes in dementia. 2: Are there behavioural syndromes?
16. Behaviour changes in dementia. 1: Point of entry data of a prospective study
17. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study
18. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
19. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia
20. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease
21. The Present Behavioural Examination (PBE): The development of an interview to measure current behavioural abnormalities
22. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome
23. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication
24. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician
25. The patients dying after long terminal phase have acidotic brains; implications for biochemical measurements on autopsy tissue
26. Protein determination with the folin phenol reagent
27. Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC
28. The molecular basis of muscarinic receptor diversity
29. Structure-activity relationships and pharmacological profile of selective tricyclic antimuscarinics
30. 2-muscarinic receptor antagonist in aged memory-impaired
31. Brain muscarinic receptor subtypes are differently affected in Alzheimer's disease and Parkinson's disease
32. Muscarinic and nicotinic cholinergic binding sites in Alzheimer's disease cerebral cortex
33. Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease
34. Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists
35. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease
36. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease
37. Cerebral correlates of psychotic symptoms in Alzheimer's disease
38. Auditory hallucinations and the temporal cortical response to speech in schizophrenia: A functional magnetic resonance imaging study
39. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies
40. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms
41. Neurochemical correlates of major depression in primary dementia
42. Cholinergic deficits-contribute to behavioral disturbance in patients with dementia
43. Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: Morphological evidence for cholinergic modulation of excitatory neurotransmission
44. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia
45. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: A double-blind, randomized, placebo-controlled trial